Clearpoint Neuro Inc
$ 14.55
-1.42%
24 Feb - close price
- Market Cap 432,838,000 USD
- Current Price $ 14.55
- High / Low $ 15.09 / 14.23
- Stock P/E N/A
- Book Value 0.56
- EPS -0.83
- Next Earning Report 2026-02-25
- Dividend Per Share N/A
- Dividend Yield 0 %
- Next Dividend Date -
- ROA -0.28 %
- ROE -1.03 %
- 52 Week High 30.10
- 52 Week Low 9.76
About
ClearPoint Neuro, Inc. is a medical device company primarily in the United States. The company is headquartered in Irvine, California.
Analyst Target Price
$29.00
Quarterly Earnings
| Sep 2025 | Jun 2025 | Mar 2025 | Dec 2024 | Sep 2024 | Jun 2024 | Mar 2024 | Dec 2023 | Sep 2023 | Jun 2023 | Mar 2023 | Dec 2022 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Reported Date | 2025-11-06 | 2025-08-12 | 2025-05-05 | 2025-02-26 | 2024-11-07 | 2024-08-07 | 2024-05-07 | 2024-03-12 | 2023-11-09 | 2023-08-08 | 2023-05-11 | 2023-03-01 |
| Reported EPS | -0.21 | -0.21 | -0.22 | -0.2 | -0.18 | -0.16 | -0.16 | -0.19 | -0.2 | -0.29 | -0.23 | -0.18 |
| Estimated EPS | -0.18 | -0.2 | -0.16 | -0.1737 | -0.17 | -0.2 | -0.19 | -0.2 | -0.25 | -0.19 | -0.18 | -0.2 |
| Surprise | -0.03 | -0.01 | -0.06 | -0.0263 | -0.01 | 0.04 | 0.03 | 0.01 | 0.05 | -0.1 | -0.05 | 0.02 |
| Surprise Percentage | -16.6667% | -5% | -37.5% | -15.141% | -5.8824% | 20% | 15.7895% | 5% | 20% | -52.6316% | -27.7778% | 10% |
Next Quarterly Earnings
| Dec 2025 | |
|---|---|
| Reported Date | 2026-02-25 |
| Fiscal Date Ending | 2025-12-31 |
| Estimated EPS | -0.22 |
| Currency | USD |
Next Dividend Records
| Dividend per share (year): | - |
| Dividend Yield | - |
| Next Dividend Date | - |
| Ex-Dividend Date | - |
Recent News: CLPT
2026-02-20 22:10:12
Clearpoint Neuro Inc (CLPT) is projected to report a loss of 20 cents per share. This information comes from a Reuters earnings preview. The article provides financial expectations for the company.
2026-02-18 08:57:22
ClearPoint Neuro (CLPT) is scheduled to release its Q4 2025 earnings before market open on Wednesday, February 25th, with analysts expecting a loss of ($0.22) per share. Despite a "Hold" consensus rating and a price target below its current share price, the company has seen significant institutional interest, including increased stakes from Millennium Management and Goldman Sachs. CEO Joseph Burnett recently sold shares, though insiders still hold a notable percentage of the stock.
2026-02-17 08:58:00
This article analyzes Clearpoint Neuro, Inc. (NASDAQ: CLPT), highlighting divergent sentiment across different time horizons and suggesting choppy conditions. It presents an exceptional 156.7:1 risk-reward setup targeting a 41.9% gain, and outlines three distinct AI-generated trading strategies for various risk profiles: Position Trading, Momentum Breakout, and Risk Hedging. The analysis includes multi-timeframe signal analysis with support and resistance levels.
2026-02-13 00:57:56
ClearPoint Neuro Inc. (CLPT) is positioned as a compelling investment in the medical devices sector with a potential upside of 116.90%. Specializing in minimally invasive surgical platforms for brain procedures, the company integrates advanced MRI techniques for precise interventions. Despite recent stock volatility and negative EPS, strong analyst sentiment, strategic collaborations, and positive revenue growth highlight its future profitability and growth potential.
2026-02-10 13:58:31
Essex Investment Management Co. LLC reduced its stake in ClearPoint Neuro, Inc. (NASDAQ:CLPT) by 28.6%, selling 92,920 shares and retaining 232,458 shares valued at approximately $5.07 million. Despite this, other institutions like Millennium Management LLC, Geode Capital Management LLC, Goldman Sachs Group Inc., and Bank of America Corp DE significantly increased their positions, bringing institutional ownership to about 30.08%. CLPT's CEO, Joseph Burnett, also sold 2,943 shares, and the company currently holds an average analyst rating of "Hold" with a consensus target price of $9.00.
2026-02-06 07:50:00
This article analyzes Clearpoint Neuro, Inc. (NASDAQ: CLPT), highlighting weak near and mid-term sentiment but a strong long-term outlook. It identifies an exceptional 160.3:1 risk-reward setup, targeting a 43.5% gain versus 0.3% risk. The analysis includes distinct institutional trading strategies for position trading, momentum breakout, and risk hedging, along with multi-timeframe signal analysis.
